Health & Research Goals
IGF-1 LR3 (Insulin-like Growth Factor-1 Long Arg3)
IGF-1 LR3 (Factor de Crecimiento Insulínico-1 Long Arg3)
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analogue of endogenous Insulin-like Growth Factor-1 (IGF-1) engine…
Primary Description
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analogue of endogenous Insulin-like Growth Factor-1 (IGF-1) engineered for dramatically extended half-life and potency. Compared to native IGF-1 (half-life ~15 minutes), IGF-1 LR3 has a half-life of approximately 20–30 hours due to two key modifications: substitution of glutamate at position 3 with arginine (R3) and addition of a 13-amino acid N-terminal extension sequence. These modifications reduce its affinity for IGF-binding proteins (IGFBPs), preventing rapid sequestration and greatly extending its bioactive window. IGF-1 LR3 is approximately 2–3x more potent than native IGF-1 at stimulating cellular anabolic pathways. NOTE: This peptide page was not found on PepedHub; content is based on established clinical knowledge.
Key Benefits
- Muscle growth
- Fat loss
- Recovery
Lyophilized powder stable at -20°C for 2 years. Reconstituted: store at 2–8°C, use within 7–14 days. Sensitive to temperature fluctuation and agitation. Reconstitute with dilute acetic acid (0.1–1% acetic acid) or BAC water per product spec. Do NOT freeze reconstituted solution.
Demonstrated Effects
- 2–3x more potent than native IGF-1 with 20–30 hour half-life (vs 15 min for native IGF-1)
- Directly stimulates muscle protein synthesis via IGF-1 receptor (IGF-1R) without requiring HGH conversion
- Promotes satellite cell proliferation and muscle hyperplasia (new fiber formation)
- Reduces IGFBP interference — longer unbound bioactive window in plasma
- Supports nitrogen retention and positive protein balance
- Enhances fat oxidation and lean mass accrual simultaneously
- Neuroprotective effects — IGF-1R expressed throughout the CNS
- Cartilage and connective tissue repair via chondrocyte stimulation
- Synergistic with HGH and GH secretagogues to amplify anabolic signaling
- Bone density improvements via osteoblast activation
Proposed Mechanisms of Action
1. IGF-1 Receptor (IGF-1R) Activation
IGF-1 LR3 binds IGF-1R with high affinity, activating the intrinsic tyrosine kinase and downstream PI3K/Akt/mTOR (protein synthesis, anti-apoptotic) and MEK/ERK (proliferation, differentiation) signaling cascades.
2. IGFBP Avoidance
Native IGF-1 is rapidly bound by IGF-binding proteins (IGFBP-1 through -6) in plasma, reducing its free bioactive fraction. The Arg3 substitution and N-terminal extension reduce IGFBP affinity by ~2–3-fold, dramatically extending free IGF-1 LR3 availability.
3. PI3K/Akt/mTOR Pathway Activation
The primary anabolic pathway downstream of IGF-1R. Akt phosphorylation activates mTORC1 which drives ribosomal S6 kinase (p70S6K) and 4EBP1 — the core regulators of protein synthesis and cell growth.
4. Satellite Cell Proliferation
IGF-1R activation in quiescent satellite cells drives their entry into the cell cycle, proliferation, and differentiation into myoblasts — enabling true muscle hyperplasia (new fiber formation).
5. Anti-Apoptotic Signaling
Akt phosphorylation downstream of IGF-1R inhibits pro-apoptotic factors (Bad, caspase-9, FOXO transcription factors), protecting muscle cells and neurons from programmed cell death during stress or atrophy.
6. Insulin-like Metabolic Effects
IGF-1 LR3 has ~6% the insulin receptor affinity of insulin but at pharmacological doses can produce insulin-like hypoglycemia — an important safety consideration requiring carbohydrate co-administration.
7. Chondrocyte and Bone Stimulation
IGF-1R activation in chondrocytes and osteoblasts drives cartilage matrix synthesis, bone formation, and epiphyseal growth plate activity.
Research Evidence & Clinical Data
Investigated Applications
Muscle Hypertrophy and Anabolism
Anecdotal: HighThe primary use in the performance community. IGF-1 LR3 directly activates IGF-1R on muscle cells, driving protein synthesis, satellite cell proliferation, and muscle hyperplasia independent of HGH levels. The extended half-life provides sustained anabolic signaling over 24 hours.
Preclinical basis: IGF-1R activates PI3K/Akt/mTOR and MEK/ERK pathways driving protein synthesis and cell proliferation. LR3 modifications prevent IGFBP sequestration, maintaining systemic bioactivity for 20–30 hours.
Recovery and Injury Healing
Anecdotal: ModerateIGF-1 directly promotes tissue repair — cartilage, tendons, muscle, and neuronal tissue all express IGF-1R. Community use for accelerating recovery from injuries and surgeries is well-established.
Preclinical basis: IGF-1 promotes chondrocyte proliferation and collagen synthesis in cartilage repair models. Satellite cell activation by IGF-1 is the primary driver of muscle repair after injury.
Neuroprotection and Cognitive Enhancement
Anecdotal: EmergingIGF-1 has established neuroprotective effects — it promotes neuronal survival, synaptic plasticity, and brain aging resistance. IGF-1 LR3 can cross the blood-brain barrier and activate CNS IGF-1 receptors.
Preclinical basis: IGF-1 promotes BDNF expression, reduces neuroinflammation, protects against Alzheimer's pathology, and supports myelination in preclinical models.
Scientific References
- 1.
- 2.IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheepAm J Physiol Endocrinol Metab2025
- 3.Optimizing IGF-I for skeletal muscle therapeuticsGrowth Horm IGF Res2014
Safety Profile
Common Side Effects
- Hypoglycemia post-injection (consume carbohydrates immediately after)
- Injection site soreness or swelling
- Increased hunger
- Temporary bloating
- Numbness or tingling (insulin-like effect)
- Hypoglycemia
- Joint pain
- Organ growth
Contraindications
- Active cancer or cancer history — IGF-1R is a potent proliferative signal (significant theoretical tumor promotion risk)
- Insulin-dependent diabetes — hypoglycemia risk compounded
- Pregnancy or breastfeeding
- Children and adolescents — growth plate effects
- Active diabetic retinopathy
- Active cancer
- Diabetes
Legal & Regulatory Status
Not FDA-approved for human therapeutic use. Native IGF-1 (mecasermin/Increlex) is FDA-approved for primary IGF-1 deficiency in children. IGF-1 LR3 is sold as a research chemical. WADA prohibited at all times (S2 — Peptide Hormones and related substances). No controlled substance scheduling in most jurisdictions, but export/import regulations vary.
No aprobado por la FDA para uso terapéutico humano. IGF-1 nativo (mecasermin/Increlex) está aprobado por la FDA para deficiencia primaria de IGF-1 en niños. IGF-1 LR3 se vende como químico de investigación. WADA prohibido en todo momento (S2 — Hormonas peptídicas y sustancias relacionadas). Sin clasificación de sustancia controlada en la mayoría de jurisdicciones, pero las regulaciones de importación/exportación varían.
Research Protocols
Dosing Protocols
Routes of Administration
intramuscular
subcutaneous
Reconstitution Guide
Pharmacokinetics
| Half-Life | Approximately 20–30 hours (vs ~15 minutes for native IGF-1). Extended due to reduced IGFBP affinity. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- IGF-1 level at 2-week intervals during cycle — target physiological upper range
- Fasting glucose monitoring — watch for insulin resistance or hypoglycemia patterns
- Injection site assessment weekly
- Monitor for soft tissue swelling, joint pain, or acromegaly-like features
- Annual cancer screening for users on long-term or repeated cycles
Critical Warning Signs
- Hypoglycemia symptoms (shakiness, sweating, confusion) — consume glucose immediately
- Severe hypoglycemia episode — seek emergency care
- Any new growths, lumps, or rapidly changing tissue — stop and evaluate
- Disproportionate organ growth (jaw, hands) — stop and consult endocrinologist
- Vision changes — ophthalmology evaluation
Featured in Stacking Protocols
Community-researched combinations involving this compound